91 related articles for article (PubMed ID: 7868643)
1. An HIV-1 protease screening assay using a non-infectious proviral clone.
Heldsinger AA; Antonucci T
J Virol Methods; 1994 Oct; 49(3):247-55. PubMed ID: 7868643
[TBL] [Abstract][Full Text] [Related]
2. Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro.
Panther LA; Coombs RW; Aung SA; dela Rosa C; Gretch D; Corey L
J Med Virol; 1999 Jun; 58(2):165-73. PubMed ID: 10335865
[TBL] [Abstract][Full Text] [Related]
3. Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor.
el-Farrash MA; Kuroda MJ; Kitazaki T; Masuda T; Kato K; Hatanaka M; Harada S
J Virol; 1994 Jan; 68(1):233-9. PubMed ID: 8254733
[TBL] [Abstract][Full Text] [Related]
4. Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide.
Misumi S; Morikawa Y; Tomonaga M; Ohkuma K; Takamune N; Shoji S
J Biochem; 2004 Mar; 135(3):447-53. PubMed ID: 15113844
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of human immunodeficiency virus type 1 protease increases intracellular cleavage of Gag and reduces virus infectivity.
Luukkonen BG; Fenyö EM; Schwartz S
Virology; 1995 Feb; 206(2):854-65. PubMed ID: 7856098
[TBL] [Abstract][Full Text] [Related]
6. A kinetic model for comparing proteolytic processing activity and inhibitor resistance potential of mutant HIV-1 proteases.
Tang J; Hartsuck JA
FEBS Lett; 1995 Jun; 367(2):112-6. PubMed ID: 7796905
[TBL] [Abstract][Full Text] [Related]
7. Formation of noninfectious HIV-1 virus particles lacking a full-length envelope protein.
Ratner L; Vander Heyden N; Garcia J; Polinsky M; Westervelt P; Becich M
AIDS Res Hum Retroviruses; 1991 Mar; 7(3):287-94. PubMed ID: 1829617
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease.
Davis DA; Brown CA; Singer KE; Wang V; Kaufman J; Stahl SJ; Wingfield P; Maeda K; Harada S; Yoshimura K; Kosalaraksa P; Mitsuya H; Yarchoan R
Antiviral Res; 2006 Nov; 72(2):89-99. PubMed ID: 16687179
[TBL] [Abstract][Full Text] [Related]
9. In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine.
Kageyama S; Mimoto T; Murakawa Y; Nomizu M; Ford H; Shirasaka T; Gulnik S; Erickson J; Takada K; Hayashi H
Antimicrob Agents Chemother; 1993 Apr; 37(4):810-7. PubMed ID: 8494379
[TBL] [Abstract][Full Text] [Related]
10. Epitope mapping of a monoclonal antibody which binds HIV-1 Gag and not the Gag-derived proteins.
Sarubbi E; Denaro M
FEBS Lett; 1993 Dec; 335(3):335-7. PubMed ID: 7505237
[TBL] [Abstract][Full Text] [Related]
11. Active human immunodeficiency virus protease is required for viral infectivity.
Kohl NE; Emini EA; Schleif WA; Davis LJ; Heimbach JC; Dixon RA; Scolnick EM; Sigal IS
Proc Natl Acad Sci U S A; 1988 Jul; 85(13):4686-90. PubMed ID: 3290901
[TBL] [Abstract][Full Text] [Related]
12. Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine.
Wagner R; Fliessbach H; Wanner G; Motz M; Niedrig M; Deby G; von Brunn A; Wolf H
Arch Virol; 1992; 127(1-4):117-37. PubMed ID: 1456888
[TBL] [Abstract][Full Text] [Related]
13. Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease.
Bechtold CM; Patick AK; Alam M; Greytok J; Tino JA; Chen P; Gordon E; Ahmad S; Barrish JC; Zahler R
Antimicrob Agents Chemother; 1995 Feb; 39(2):374-9. PubMed ID: 7726501
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the protease gene of human immunodeficiency virus type 1 affect release and stability of virus particles.
Park J; Morrow CD
Virology; 1993 Jun; 194(2):843-50. PubMed ID: 8503189
[TBL] [Abstract][Full Text] [Related]
15. Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins.
Wu X; Liu H; Xiao H; Kappes JC
Virology; 1996 May; 219(1):307-13. PubMed ID: 8623547
[TBL] [Abstract][Full Text] [Related]
16. A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer.
Hu K; Clément JF; Abrahamyan L; Strebel K; Bouvier M; Kleiman L; Mouland AJ
J Virol Methods; 2005 Sep; 128(1-2):93-103. PubMed ID: 15951029
[TBL] [Abstract][Full Text] [Related]
17. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.
Dis Markers; 1990; 8(3):162-3. PubMed ID: 2125537
[No Abstract] [Full Text] [Related]
18. Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein.
Wu X; Liu H; Xiao H; Conway JA; Hunter E; Kappes JC
EMBO J; 1997 Aug; 16(16):5113-22. PubMed ID: 9305652
[TBL] [Abstract][Full Text] [Related]
19. Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication.
Fitzon T; Leschonsky B; Bieler K; Paulus C; Schröder J; Wolf H; Wagner R
Virology; 2000 Mar; 268(2):294-307. PubMed ID: 10704338
[TBL] [Abstract][Full Text] [Related]
20. Gag-Gag interactions in the C-terminal domain of human immunodeficiency virus type 1 p24 capsid antigen are essential for Gag particle assembly.
Zhang WH; Hockley DJ; Nermut MV; Morikawa Y; Jones IM
J Gen Virol; 1996 Apr; 77 ( Pt 4)():743-51. PubMed ID: 8627263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
